PTK2 and cancer: In a prior study, we identified fibronectin-binding sequences within the extracellular domain of dysadherin and developed a synthetic peptide that blocks this interaction, thereby disrupting integrin/FAK/YAP signaling and suppressing tumor growth and metastasis in colorectal cancer.29 The peptide selectively reduced the viability of dysadherin-expressing cancer cells.